DRUG — BRIGHT MINDS BIOSCIENCES INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1827401 ·
Last close
$77.03
Market Cap
$755.77M
52W High
$92.00
52W Low
$56.47
ADV30
193,858
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,319,423 | -10,459,627 | 312,365,111 | 309,691,863 | 3,832,687 |
| Dec 2025 | 0 | — | -6,904,082 | -7,565,318 | 90,879,853 | 89,047,867 | 1,599,304 |
| Sep 2025 | 0 | — | -5,664,542 | -4,085,603 | 84,421,539 | 82,908,589 | 2,376,616 |
| Jun 2025 | 0 | — | -3,296,310 | -5,242,970 | 52,497,560 | 51,387,560 | 667,833 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,833,944
Investing CF
—
Financing CF
$275,158,777
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-64,603,262
Inventory
—
Receivables
$1,139,911
ST Investments
—
EBIT TTM
$-31,184,357
Pretax Income TTM
$-27,353,518
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -13,937,584 | -12,229,348 | 84,421,539 | 2,376,616 | — | -8,691,619 |
| Sep 2024 | 0 | -2,822,767 | -2,801,946 | 6,104,602 | 568,259 | — | -1,850,186 |
| Sep 2023 | 0 | -7,386,414 | -7,372,225 | 6,879,072 | 280,856 | — | -7,024,265 |
| Sep 2022 | 0 | -14,975,092 | -14,964,941 | 12,086,984 | 1,544,472 | — | -13,587,116 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.92
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $75.00 · spot: $81.54 · call volume: 2 · put volume: 22Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MNPR | Monopar Therapeutics | $747.47M | $111.36 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $743.94M | $35.31 | — |
| NVCT | Nuvectis Pharma, Inc. | $779.21M | $23.87 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $732.79M | $9.14 | — |
| OCS | Oculis Holding AG | $731.86M | $13.18 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
2026-07-23 13:55 · Yahoo
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
2026-07-22 16:00 · Yahoo
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
2026-08-10 13:55 · Yahoo
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
2026-03-06 15:15 · Yahoo
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
2026-02-19 02:31 · Yahoo
Canadian Securities Exchange Reports January 2026 Performance Figures
2026-02-17 15:09 · Yahoo
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
2026-01-09 16:56 · Yahoo
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
2026-01-08 02:33 · Yahoo
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
2026-01-06 21:00 · Yahoo
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
2026-01-06 12:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.